RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288

Benzinga · 1d ago
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.